Tissue factor (TF) has been implicated in tumor progression and immune regulation, but its cellular sources and relationship with immune infiltration in ovarian cancer remain incompletely defined. We integrated single-cell RNA sequencing (GSE232314), analyses of The Cancer Genome Atlas (TCGA) ovarian cancer cohort, and multiplex immunofluorescence in an independent 25-case tissue microarray (TMA). Single-cell analysis showed that TF expression was concentrated in tumor epithelial cells and a discrete endothelial subpopulation, with minimal expression in immune and other stromal compartments. In the TCGA cohort, TF expression was not significantly associated with tumor stage, grade, disease-free survival, or overall survival. In TF-stratified analyses, however, high CD8+ T cell infiltration was associated with improved survival in the low-TF expression subgroup (HR = 0.60) but with worse survival in the high-TF subgroup (HR = 1.72); high M1 macrophage infiltration was associated with improved survival only in the low-TF subgroup. TF expression correlated negatively with estimated CD8+ T cell, memory B cell, and M1 macrophage infiltration and positively with naïve B cell infiltration. In the TMA cohort, high-TF tumors showed significantly lower CD56+ NK-cell and CD68+ macrophage infiltration and a lower CD68/CD163 ratio. Together, these findings show cross-sectional associations between TF expression and reduced measured abundance of several antitumor immune populations and a stratum-dependent association between CD8+ T cell infiltration and survival. These associations were not fully concordant between the transcriptomic (TCGA) and protein-level (TMA) cohorts and require prospective, formally tested validation. TF warrants further investigation as a candidate immune-context biomarker in ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Mohiuddin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: